Add Row 
Add 
Add Element 
Add Row 
Revolutionary Psoriasis Treatments: A New Era in Dermatology
Hosted at the Elevate Derm West 2024 conference, Dr. Jason Hawkes provided valuable insights into the cutting-edge developments in psoriasis therapies. MedSpa owners and aesthetic professionals should note the breakthrough understanding of psoriasis’ immunological pathways, namely IL-23 and IL-17, which has significantly bolstered the efficacy of biologic treatments.
The Promise of Innovative Oral Therapies
While biologics have taken center stage, the realm of oral treatments for psoriasis has lagged but is catching up swiftly. Enter deucravacitinib, a selective TYK2 inhibitor, marking a significant milestone with its commendable efficacy and reduced adverse reactions compared to its predecessors like apremilast. For patients and providers, this means a step closer to effective alternative solutions when biologics are not an option.
Future Predictions and Trends in Treatment
Looking to the future, Dr. Hawkes highlighted the potential of second-generation TYK2 inhibitors and oral IL-23 receptor inhibitors. These innovations promise to bridge the efficacy gap seen in current oral therapies versus biologics, offering nearly 40% of patients full skin clearance. For MedSpa professionals, staying ahead of these trends not only enhances service offerings but ensures preparedness in using these therapies as part of holistic skincare solutions.
Write A Comment